Zealand partner Boehringer begins Phase I trials for two obesity and / or diabetes drugs
Zealand Pharma has announced the launch of two Phase I clinical trials by its partner Boehringer Ingelheim to investigate a glucagon / GLP-1 agonist and an amylin analogue for the treatment of obesity and / or type 2 diabetes.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Clinical Trials | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | New Zealand Health | Obesity | Pharmaceuticals